Utkina-Sosunova, Irina
Chiorazzi, Alessia
de Planell-Saguer, Mariangels
Li, Hai
Meregalli, Cristina
Pozzi, Eleonora
Carozzi, Valentina Alda
Canta, Annalisa
Monza, Laura
Alberti, Paola
Fumagalli, Giulia
Karan, Charles
Moayedi, Yalda
Przedborski, Serge
Cavaletti, Guido
Lotti, Francesco
Funding for this research was provided by:
Fondazione Cariplo (2019-1482)
Associazione Italiana per la Ricerca sul Cancro (IG 2021 ID 25788)
Italian Ministry of Research National Research (PRIN 2017, protocol number 2017ZFJCS3)
Thompson Family Foundation Initiative at Columbia University (GT005845)
Article History
Received: 5 January 2024
Accepted: 14 August 2024
First Online: 20 August 2024
Competing interests
: F. L. is a co-founder and President of a startup company working on antisense oligonucleotide therapeutics. The rest of the authors do not have any competing interests.